Tocagen (NASDAQ:TOCA) Lowered to Neutral at Robert W. Baird

Robert W. Baird cut shares of Tocagen (NASDAQ:TOCA) from an outperform rating to a neutral rating in a research note issued to investors on Thursday morning, The Fly reports.

Several other research firms have also commented on TOCA. HC Wainwright reissued a buy rating on shares of Tocagen in a report on Friday, August 9th. Zacks Investment Research lowered shares of Tocagen from a buy rating to a hold rating in a report on Wednesday, September 4th. ValuEngine raised shares of Tocagen from a hold rating to a buy rating in a report on Thursday, August 1st. Chardan Capital reissued a buy rating and issued a $10.00 target price on shares of Tocagen in a report on Wednesday, May 22nd. Finally, Citigroup began coverage on shares of Tocagen in a report on Thursday, May 30th. They issued a buy rating on the stock. Nine analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of $12.95.

TOCA stock traded up $0.10 during mid-day trading on Thursday, hitting $1.03. The stock had a trading volume of 3,125,454 shares, compared to its average volume of 256,770. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.86. Tocagen has a 52 week low of $0.73 and a 52 week high of $15.80. The firm has a market capitalization of $89.61 million, a P/E ratio of -0.42 and a beta of 4.07. The firm has a fifty day simple moving average of $4.35 and a 200 day simple moving average of $7.28.

Tocagen (NASDAQ:TOCA) last released its earnings results on Thursday, August 8th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.04. Tocagen had a negative net margin of 300.42% and a negative return on equity of 115.81%. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.50 million. As a group, equities analysts expect that Tocagen will post -2.67 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA grew its holdings in shares of Tocagen by 72,350.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,347 shares of the company’s stock valued at $47,000 after purchasing an additional 4,341 shares during the last quarter. Creative Planning bought a new stake in shares of Tocagen during the 1st quarter valued at approximately $117,000. Parametric Portfolio Associates LLC bought a new stake in shares of Tocagen during the 2nd quarter valued at approximately $75,000. Bank of America Corp DE grew its holdings in shares of Tocagen by 28.6% during the 4th quarter. Bank of America Corp DE now owns 14,584 shares of the company’s stock valued at $120,000 after purchasing an additional 3,240 shares during the last quarter. Finally, A.R.T. Advisors LLC bought a new stake in shares of Tocagen during the 2nd quarter valued at approximately $114,000. 35.43% of the stock is currently owned by institutional investors.

Tocagen Company Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Further Reading: Trading Penny Stocks

The Fly

Analyst Recommendations for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit